

RESPIRATORY AND INFLAMMATION (R&I) MEDICINES

MARKETED PRODUCTS

Symbicort Turbuhaler (budesonide/formoterol in a dry powder inhaler) is a combination of an inhaled corticosteroid and a fast onset, long-acting bronchodilator for the treatment of asthma and COPD. *Symbicort Turbuhaler* is also available as *Symbicort SMART*.

Symbicort pMDI (budesonide/formoterol in a pressurised metered-dose inhaler) for the treatment of asthma.

Pulmicort (budesonide) is a corticosteroid anti-inflammatory inhalation drug that helps prevent symptoms and improves the control of asthma.

Pulmicort Respules (budesonide inhalation suspension) is the first and only nebulised corticosteroid in the US for the treatment of asthma in children as young as 12 months.

Rhinocort (budesonide) is a nasal steroid treatment for allergic rhinitis (hay fever), perennial rhinitis and nasal polyps.

Oxis (formoterol) is a fast onset, long-acting beta-agonist therapy for treating asthma and COPD.

Accolate (zafirlukast) is an oral leukotriene receptor antagonist for the treatment of asthma.

2007 IN BRIEF

- > **Symbicort sales of \$1.6 billion, up 22%.**
- > **Symbicort pMDI for long-term maintenance treatment of asthma launched in the US to specialists and primary care physicians.**
- > **Outside the US, Symbicort SMART now launched in over 40 countries.**
- > **Pulmicort continued to grow with sales of over \$1 billion, up 10%.**
- > **Acquisition of MedImmune strengthened the R&I portfolio.**
- > **Acquisition of Verus Pharmaceuticals' paediatric asthma business in North America.**
- > **European Patent Office revoked the European combination patent for Symbicort for use in asthma. Other patent property and data exclusivity for Symbicort not affected by the decision.**

PERFORMANCE

	2007			2006			2005	2007 compared to 2006		2006 compared to 2005	
	Sales \$m	Growth underlying \$m	exchange effects \$m	Sales \$m	Growth underlying \$m	exchange effects \$m		Growth underlying %	Growth reported %	Growth underlying %	Growth reported %
<i>Symbicort</i>	1,575	265	126	1,184	182	(4)	1,006	22	33	18	18
<i>Pulmicort</i>	1,454	128	34	1,292	132	(2)	1,162	10	13	11	11
<i>Rhinocort</i>	354	(16)	10	360	(27)	-	387	(4)	(2)	(7)	(7)
<i>Oxis</i>	86	(9)	7	88	(3)	-	91	(10)	(2)	(3)	(3)
<i>Accolate</i>	76	(6)	1	81	9	-	72	(7)	(6)	13	13
Other	166	7	13	146	(9)	-	155	5	14	(6)	(6)
Total	3,711	369	191	3,151	284	(6)	2,873	12	18	10	10

PIPELINE

Compound	Mechanism	Areas under investigation	Phase			Estimated filing date		
			I	II	III	Europe	US	
NCEs								
AZD9056	ion channel blocker (P2X7)	rheumatoid arthritis	■	■			2012	2012
AZD1981	prostaglandin receptor antagonist	asthma	■	■				
AZD5672	chemokine antagonist (CCR5)	rheumatoid arthritis	■	■			2012	2012
MEDI-528	anti-IL-9 antibody	asthma	■	■				
AZD4818	CCR1 antagonist	COPD	■					
CAT-354	anti-IL-13 antibody	asthma	■					
AZD5904	MPO inhibitor	COPD	■					
AZD1744	dual CCR3/H1 receptor antagonist	COPD	■					
AZD1236	matrix metalloproteinase inhibition	COPD	■					
AZD9668	neutrophil elastase inhibitor	COPD	■					
MEDI-563	anti-IL-5R antibody	asthma	■					
MEDI-545	anti-IFN α antibody	SLE, myositis	■					
Pneumococcal vaccine ¹	pneumococcal vaccine	streptococcus pneumoniae	■					
AZD3199	iLABA	asthma/COPD	■					
CAM-3001	anti-GM-CSFR antibody	rheumatoid arthritis	■					
Line extensions								
<i>Symbicort pMDI</i>	inhaled steroid/fast onset, long-acting β_2 agonist	asthma	■	■	■		Filed ²	Launched ³
<i>Symbicort pMDI</i>	inhaled steroid/fast onset, long-acting β_2 agonist	COPD	■	■	■		Filed ²	2Q 2008

¹ Partnered product.

² To be supplemented in 2008 with data supporting two additional strengths.

³ US approval based on 12 years and above.

For discontinued projects see page 30.